{"organizations": [], "uuid": "01f391dd822643aa7e64c46e844144e0ac84b660", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180307.html", "section_title": "Archive News &amp; Video for Wednesday, 07 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/merck-co-eisai-oncology/merck-eisai-sign-deal-to-further-develop-sell-eisai-cancer-drug-idUSL2N1QP250", "country": "US", "domain_rank": 408, "title": "Merck, Eisai sign deal to further develop, sell Eisai cancer drug", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.998, "site_type": "news", "published": "2018-03-08T06:17:00.000+02:00", "replies_count": 0, "uuid": "01f391dd822643aa7e64c46e844144e0ac84b660"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/merck-co-eisai-oncology/merck-eisai-sign-deal-to-further-develop-sell-eisai-cancer-drug-idUSL2N1QP250", "ord_in_thread": 0, "title": "Merck, Eisai sign deal to further develop, sell Eisai cancer drug", "locations": [], "entities": {"persons": [{"name": "keytruda", "sentiment": "none"}, {"name": "bill berkrot", "sentiment": "none"}, {"name": "matthew lewis", "sentiment": "none"}, {"name": "merck", "sentiment": "none"}], "locations": [{"name": "japan", "sentiment": "none"}, {"name": "new york", "sentiment": "none"}], "organizations": [{"name": "eisai", "sentiment": "negative"}, {"name": "merck", "sentiment": "negative"}, {"name": "eisai co ltd", "sentiment": "negative"}, {"name": "reuters) - merck & co", "sentiment": "neutral"}, {"name": "astrazeneca plc", "sentiment": "none"}, {"name": "lenvima", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 7 (Reuters) - Merck & Co and Japan’s Eisai Co Ltd on Wednesday announced a potential multibillion-dollar collaboration to develop and sell Eisai’s cancer drug Lenvima, which is already approved in many countries for two uses.\nThe deal, under which Lenvima will be developed for several types of cancer alone and in combination with Merck’s immunotherapy Keytruda, could be worth up to $5.76 billion to Eisai, but most of that would be contingent on eventual sales.\nMeanwhile, Merck will be entitled to half of all global Lenvima sales, even for its already-approved uses for thyroid cancer and in combination with another drug for kidney cancer.\nThe deal is similar to a multibillion-dollar oncology collaboration Merck struck with AstraZeneca Plc last July.\nReporting by Bill Berkrot in New York Editing by Matthew Lewis\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-03-08T06:17:00.000+02:00", "crawled": "2018-03-08T17:07:46.003+02:00", "highlightTitle": ""}